Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn`s Disease

Study:

A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn`s Disease

Rationale:

n/a

Purpose:

Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn`s disease when compared to placebo (an inactive substance)

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Crohn`s Disease Drug: Adalimumab (D2E7) Phase 2

Verified by Abbott August, 2006

Sponsored by: Abbott
Information provided by: Abbott
ClinicalTrials.gov identifier: NCT00055523

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Cleveland Clinic Florida
Weston, Florida 33331
United States

Stephen B Hanauer, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site